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Objective: To perform a systematic review and multiple-treatment meta-analysis for the
treatment of premature infants with post-hemorrhagic ventricular dilatation (PHVD), to
prevent death or long-term neuro-disability.
Design/Method: A systematic reviewwas performed using PubMed, EMBASE, and the
Cochrane Library. A free-word search was performed to identify likely relevant literature
intervention trials of PHVD in preterm infants. Initially, network mapping was performed
followed by performing a Bayesian random-effects model using the Markov chain Monte
Carlo method. Areas under the cumulative ranking curve (SUCRA) were calculated
as a measure of the probability that each intervention was likely to be the 1st, 2nd,
3rd, etc. best therapy. Primary outcome measure was death or moderate or severe
neurodevelopmental outcome at or beyond 12 months of corrected age.
Results: Ten different trials were identified, enrolling 700 individuals (449 for the primary
outcome). Seven intervention categories were identified, and of the 15 possible pair
comparisons, 6 have been studied directly. In the multiple-treatment meta-analysis, no
comparison reached conventional levels of statistical significance. Drainage Irrigation and
Fibrinolytic Therapy (DRIFT) had the highest probability of being the best treatment for the
primary outcome (82.1%), followed by CSF removal (10.8%), conservative management
(6.7%), and then diuretic therapy (0.4%).
Conclusions: PHVD is a significant cause of death and disability in developed countries,
yet few therapeutic options have so far been trialed. While new therapies are urgently
needed for these infants, at present, NMA shows that DRIFT appears to be the most
likely candidate to improve outcomes after sIVH.
Keywords: premature birth, brain injury, preterm, intraventricular hemorrhage, post-hemorrhagic ventricular
dilatation
INTRODUCTION
Around 1 in 10 infants is born preterm, and survival of these infants has increased significantly
over the last two decades (1, 2). However, brain injury, associated with two different patterns
of damage, periventricular leukomalacia (PVL) and intraventricular hemorrhage (IVH), is
common in infants born preterm, with potentially devastating personal impacts and significant
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population effects. While the risk of PVL in infants below 32
weeks has halved over the last two decades, the risk of IVH has
stayed similar despite improvements in antenatal and neonatal
care and while new interventions, such as delayed cord clamping,
antenatal steroids, and intrapartum care, appear to reduce the
risk of IVH, the overall risk of IVH remains high (3–6).
Consequently, it now represents the most common cause
of neurological disability in the survivors (7). Those infants
who develop severe intraventricular hemorrhage (sIVH) are at
high risk of developing post-hemorrhagic ventricular dilatation
(PHVD), a condition with high rates of long-term disability with
conditions such as cerebral palsy (CP), sensory problems, and
cognitive deficits (8, 9). In addition to the personal impact, the
care of these premature infants who grow up with potentially
disabling brain injury is expensive, with economic impacts to
health care, the families involved, educational systems, and
society at large (10, 11).
However, while reducing neonatal brain injury remains a
research priority, no standardized treatment for these vulnerable
infants appears to exist, although a number of treatments
designed to prevent ongoing brain injury after sIVH and
subsequent PHVD have been studied (12–26). This work aims
to use Network Meta-analysis (NMA) methodology to allow
the comparison of different treatment modalities for PHVD,
combining the direct evidence of comparisons trailed, and
deriving indirect assessments to help identify the most efficacious
treatment. To our knowledge, NMA has not been applied to
interventions targeted at preventing the complications and the
neurodevelopmental sequelae after development of PHVD.
METHODS AND MATERIALS
Study Selection and Data Collection
Criteria for inclusion were based on previous meta-analyses in
this area and methodology was based on the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses guidelines (27–
30). Systematic review was performed by all three authors using
PubMed (1966–2018), EMBASE (1974–2018), and the Cochrane
Library. A free-word search was performed (Appendix 1) to
identify likely relevant literature. The search strategy was piloted
to ensure that it identified studies already known by the authors
to be relevant. Searches were limited to those with English
language abstracts and for research in human subjects.
Three quantitative analyses were of interest: (i) death, (ii)
neurodevelopmental disability, and (iii) ventriculo-peritoneal
shunt surgery. The titles obtained from database searching were
sifted to exclude duplicates and those clearly not relevant to the
review. Abstracts of those remaining were examined and tested
against the inclusion criteria.
• Randomized or quasi-randomized controlled trials for the
treatment of PHVD
• At least one measure out of
◦ Neurodevelopmental outcomes at or beyond 12 months
of age
◦ Mortality
◦ Ventriculo-peritoneal shunt surgery
• Randomized or quasi-randomized intervention trials
Full texts were obtained for those articles likely to be eligible and
reviewed once more. The process was performed independently
by all three authors. References in the papers were checked
to identify any other possible relevant studies. Data were
extracted on the characteristics of the individual studies. All
three authors independently reviewed the papers identified
and confirmed eligibility and the quality rating. Studies were
assessed on a quality rating of adequate, unclear, or inadequate
on the categories of random allocation, concealment, and
blinding. Primary outcome measure was death or moderate or
severe neurodevelopmental outcome at or beyond 12 months
of corrected age (using any standardized measure). Where
developmental outcomes were reported in a number of papers,
the reported primary outcome of the study was used. An arbitrary
control group was defined as treatment for PHVD only being
instigated once head growth was excessive or there were clinical
signs or raised intracranial pressure mandating treatment. Other
interventions were grouped by consensus by two of the authors
prior to analyses being performed (DO and DH). Intention-
to-treat analysis was used where available. All three authors
assessed the risk of bias in trials using the Cochrane risk of
bias tool, with discrepancies resolved by consensus (31). Where
composite outcomes of death and/or VP shunt or disability were
not provided, they were calculated if possible from the presented
data. Where data were unavailable, we assumed that infants who
died before discharge from the neonatal unit did not receive
VP shunts. Authors of included papers were not approached
for missing data or where queries about a studies’ methodology
due to the length of time since the publications of many of the
manuscripts included.
Statistical Analysis
Network mapping was performed with the size of the nodes
proportional to the sample size and the thickness of the
connecting lines proportional to the number of trials. We then
performed a Bayesian random-effects model using the Markov
chainMonte Carlo method. The results were reported as ORwith
95% confidence intervals. We used p < 0.05 as a conventional
level of significance. The areas under the cumulative ranking
curve (SUCRA) were calculated as a measure of the probability
that each intervention was the best for each of the outcome
measures, and for the primary outcome, we also derived the
probabilities that each therapy is likely to be the 1st, 2nd, 3rd,
etc. best therapy (32).
Analyses were repeated for the following outcomes:
1. Death or moderate or severe neurodevelopmental
impairment at or beyond 12 months of age
2. Moderate or severe neurodevelopmental impairment at or
beyond 12 months of age
3. Death in the neonatal period, or before 1 year of age
4. Requiring ventriculo-peritoneal shunt surgery in the neonatal
period, or before 1 year of age
5. Requiring ventriculo-peritoneal shunt surgery or death in the
neonatal period, or before 1 year of age
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An assumption behind multiple-treatment meta-analysis is that
direct and indirect evidence on comparisons do not disagree
(coherence). To estimate this, we planned to calculate the direct
and indirect OR where possible; however, due to the limited
amount of studies reporting the primary outcome, we were
unable to test if the direct and indirect assessments were coherent.
Finally, an a priori sensitivity analysis was planned excluding
those studies that were considered “inadequate” on any quality
measures. All analyses were performed using Stata 14. Results are
presented as OR (95% confidence interval).
Public and Patient Involvement
Patients or members of the public were not involved
in the design, or conduct, reporting, or dissemination
plan of this research.
RESULTS
Literature Search
Databases were searched on 10/09/2018 and, after removal of
duplicates, produced a list of 3445 publications. Of these, 36
abstracts were screened, and of these, a total of 11 full-text
papers were reviewed, all of which fulfilled the inclusion criteria
(13, 14, 16–22, 24, 25). Four systematic reviews were identified
(27, 29, 33, 34) and a further three likely papers were identified
from the references of the full-text papers and the existing
reviews. These three additional papers were reviewed and all were
included in the analysis, leaving a total of 14 papers [Appendix 2;
(13–26)] from 10 different trials. The earliest publication dates
were from 1980 (15), and the most recent dates were from
2019 (20). Overall, 700 individuals were randomly assigned and
were included in at least one multiple-treatment meta-analysis,
although only 449 infants have been enrolled in trials that have
reported the primary outcome. All studies were two-armed trials.
Further details are shown in Appendix 3.
Six categories of intervention were identified by the authors:
1) Control (defined as above) (13–17, 19–21, 23–26)
2) Tapping of CSF prior to symptoms or excessive head growth
(16, 17)
3) Diuretic therapy (23–25)
4) Drainage Irrigation and Fibrinolytic Therapy (DRIFT) (13,
18, 19)
5) Fibrinolytic therapy (21, 22)
After discussion between authors regarding one paper
randomizing infants between CSF tapping at conventional
levels (2 above) and early tapping, and an additional category
was added (6) (Early CSF tapping) to accommodate this
intervention (20).
A total of four studies reported an eligible
neurodevelopmental measure (13, 19, 24–26), while all reported
mortality or shunt usage during the neonatal period or during the
first year of life. Five studies were European (13, 17, 20, 22, 24),
four were based in the USA (14, 15, 23, 26), and 1 was based in
Turkey (21). All studies use some form of imaging to diagnose
IVH. All studies but two had a control group compatible with
our pre-defined criteria; Luciano, in contrast, randomized
between diuretic treatment in one arm and streptokinase in
the other (22) and De Vries used two different thresholds of
CSF tapping (discussed above) (20). One study (15) used an
alternative number to allocate treatment arms, while a further
three did not specify the randomization methods (21, 23, 35). VP
shunt criteria were defined in all studies except two (15, 21). Of
the four trials that reported neurodevelopmental data, three were
considered adequate (13, 16, 17, 19, 24, 25) and one was unclear
(26). No trial was able to blind clinicians to the intervention. A
summary of quality assessments is shown in Figure 1.
Individual Study Findings
Two studies investigated the use of furosemide and
acetazolamide vs. standard treatment/LPs. Libenson (23)
included a total of 16 infants who received either acetazolamide
and frusemide, or daily LPs. They reported a reduction in VP
shunts (10 vs. 50%) although there was crossover between
treatment arms. Kennedy et al. (24, 25) also compared
acetazolamide and frusemide to a control group and reported a
higher rate of death and/or ventricular shunt placement in the
intervention arm [RR 1.42 (1.06–1.90); p = 0.026] and worse
developmental outcomes [e.g., RR 1.67 (1.23–2.28) for motor
impairment]. Mantovani et al. (15), Dykes et al. (26), Anwar
et al. (14), and the Ventriculomegaly Trial Group (16) compared
frequent LP to conservative treatment, but none reported a
difference in VP shunts or death between these treatment arms.
De Vries et al. (20) randomized 126 infants with PHVD to
intervention of repeat CSF tapping to two different thresholds
with no difference in the primary outcome of VP shunt or
death (p = 0.45). Two small studies have investigated the use
of intraventricular streptokinase; Luciano et al. (22) found no
difference in the rate of VP shunt between the two groups while
Yapicioglu et al. (21) reported an increased need for VP shunt in
the streptokinase group (83 vs. 50%). Finally, the DRIFT study
included a total of 70 infants who were randomized to either
intraventricular drainage, irrigation, and fibrinolytic therapy
with tissue plasminogen activator (DRIFT) or to standard
treatment (13). This study was closed early due a minimum
chance that the short-term primary outcome would identify
a difference between groups (VP shunt or death). There was
no difference in the primary outcome of reducing the rates of
VP shunt surgery or death but an analysis of developmental
outcomes in infants at 2 years corrected age found evidence of
improved neurodevelopment [adjusted OR of 0.17 (0.05–0.57)].
Quantitative Synthesis
Figure 2 shows the resultant network of eligible comparisons
from the multiple-treatment meta-analysis.
Of the 15 possible pair comparisons, 6 have been studied
directly. Table 1 summarizes the results of the multiple-
treatment meta-analysis for the pre-specified outcomes [e.g.,
compared to control diuretics, which appeared to have a higher
OR of the primary outcome (OR 1.17 (0.99–1.39)], while
compared to diuretics, DRIFT had a lower OR [OR 0.69 (0.44–
1.07)]. Repeating the analysis for the other outcomes showed
similar results. No comparison reached conventional levels of
statistical significance.
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FIGURE 1 | Quality measures.
FIGURE 2 | Network eligible comparisons for the multiple-treatment
meta-analysis.
Table 2 and Figure 3 shows the SURCRA for each treatment
and outcomes measured. DRIFT had the highest probability
of being the best treatment for the primary outcome (82.1%),
followed by CSF removal (10.8%), conservative management
(6.7%), and then diuretic therapy (0.4%). No study was able to
blind clinicians delivering the treatment, and so no additional
analysis was performed.
DISCUSSION
We have found in this work that little evidence exists to directly
differentiate any proposed or trialed therapy for PHVD. Diuretic
therapy appeared to be detrimental, and ranking of therapies
appeared to show that DRIFT may by the most efficacious.
However, despite the significant impact of this disease, only 700
infants have ever been enrolled in an intervention trial, and
further studies are desperately needed.
Limitations of this work include the heterogeneity of the
infants enrolled, in part due to the wide time frame recruitment
across the studies (1980–2019). Neonatal care has changed
significantly during this time, with new therapies such as
antenatal steroids and surfactant, and the reduction in other
treatments such as postnatal steroids. Despite this, the control
arm of these trials appears remarkably similar over the 40
years investigated, with VP shunt insertion after development of
PHVD still the standard treatment of choice. The biggest and
perhaps most influential trials have all been performed in the last
20 years and had infants of similar gestation, with similar control
group interventions. We have used a random effects model to
allow for increased uncertainty in this work, but the lack of
precision is likely due to the small numbers included (around
700 infants involved in these randomized controlled trials) rather
than heterogeneity.
The timing of intervention in each study makes the
comparison of treatments in this using thismethodology difficult.
For example, in some of the trials, lumbar punctures were used to
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TABLE 1 | Comparisons between different treatment groups for direct and indirect outcome measures.
Treatment comparison Moderate or severe
neuro-disability, or
death
Moderate or severe
neuro-disability
VP shunt or death VP shunt Death
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
Compared to Control
CSF removal 1.01 (0.86–1.19) 0.921 0.87 (0.45–1.70) 0.689 0.96 (0.8–1.15) 0.652 0.97 (0.75–1.24) 0.791 0.91 (0.53–1.57) 0.739
Diuretics 1.17 (0.99–1.39) 0.062 1.05 (0.47–2.34) 0.905 1.20 (0.93–1.54) 0.165 1.07 (0.79–1.44) 0.676 1.58 (0.81–3.08) 0.179
DRIFT 0.80 (0.53–1.22) 0.302 0.87 (0.35–2.17) 0.759 0.97 (0.62–1.53) 0.91 1.04 (0.6–1.79) 0.89 0.58 (0.15–2.28) 0.439
Early CSF removal 0.80 (0.47–1.37) 0.421 0.80 (0.39–1.67) 0.556 0.77 (0.26–2.32) 0.645
Fibrinolytics 1.20 (0.52–2.77) 0.675 1.41 (0.70–2.84) 0.342 1.26 (0.20–7.76) 0.806
Compared to CSF Removal
Diuretics 1.16 (0.92–1.47) 0.20 1.20 (0.42–3.42) 0.73 1.25 (0.91–1.70) 0.16 1.1 (0.75–1.63) 0.62 1.73 (0.73–4.10) 0.21
DRIFT 0.80 (0.51–1.24) 0.32 0.99 (0.32–3.09) 0.99 1.02 (0.62–1.65) 0.95 1.07 (0.59–1.96) 0.81 0.64 (0.15–2.78) 0.55
Early CSF removal 0.84 (0.51–1.39) 0.49 0.83 (0.42–1.65) 0.60 0.85 (0.33–2.20) 0.73
Fibrinolytics 1.25 (0.53–2.94) 0.61 1.45 (0.69–3.07) 0.33 1.38 (0.21–9.22) 0.74
Compared to Diuretic
DRIFT 0.69 (0.44–1.07) 0.10 0.82 (0.24–2.79) 0.76 0.81 (0.48–1.37) 0.44 0.97 (0.52–1.82) 0.94 0.37 (0.08–1.68) 0.20
Early CSF removal 1.49 (0.37–1.21) 0.19 0.75 (0.34–1.66) 0.48 0.49 (0.14–1.77) 0.28
Fibrinolytics 1.00 (0.45–2.23) 1.00 1.32 (0.64–2.71) 0.45 0.80 (0.13–4.91) 0.81
Compared to DRIFT
Early CSF removal 0.82 (0.41–1.66) 0.59 0.77 (0.31–1.92) 0.58 1.32 (0.23–7.59) 0.76
Fibrinolytics 1.23 (0.47–3.19) 0.67 1.35 (0.56–3.29) 0.51 2.15 (0.22–20.84) 0.51
Compared to Early CSF Removal
Fibrinolytics 1.49 (0.55–4.04) 0.43 1.75 (0.63–4.83) 0.28 1.63 (0.19–13.62) 0.65
TABLE 2 | SUCRA for probability of most efficacious treatment for different outcomes.
Treatment Outcome
Moderate/severe
neuro-disability or death
Moderate/severe
neuro-disability
Death VP shunt VP shunt or death
Control 0.6 0.4 0.5 0.5 0.5
CSF removal 0.5 0.6 0.6 0.6 0.6
Diuretic treatment 0.1 0.4 0.2 0.4 0.2
DRIFT 0.9 0.6 0.8 0.5 0.6
Early CSF removal – – 0.6 0.7 0.8
Fibrinolytics – – 0.4 0.2 0.3
reduce the size of already distended ventricles compared (13) to
preventing further enlargement through early intervention (23).
The differences in the randomization thresholds may contribute
to some of the variation seen in the outcome measured (e.g., the
percentage of VP shunts required).
PHVD remains a significant problem in the developed world.
There are around 8,000 preterm infants born 32 weeks gestation
in England alone each year, and around 483 (6%) of these
develop a sIVH (7). Overall, around 700 infants a year develop
sIVH after birth, and most of these will develop some degree
of motor or cognitive disability (13). In all the work reviewed
here, mortality was high, and many infants who survive have
complex developmental needs, a population impact likely higher
than neonatal hypoxic–ischemic encephalopathy (36) or Trisomy
21 (37), with a corresponding burden to the NHS (in future
healthcare needs) and society. With this in mind, we find the lack
of recent trials disappointing, and this appears to be a vital area
for new biomedical research.
In this work, DRIFT is likely to be the most efficacious
treatment. Recent presentation of a secondary analysis of school
age neurodevelopmental outcomes from this trial appears to
show similar results to those used in this work on a subset
of the initial trial group (38). While this recent work was a
secondary analysis, the results are in parallel with those at 2 years,
with children assessed at 10 years, after adjusting for gender,
birthweight, and grade of IVH, with cognitive quotient being, on
average, 23.47 points higher than those who received standard
treatment (p= 0.009).
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FIGURE 3 | Probabilities of each therapy being the 1st, 2nd, 3rd, or 4th best treatment for the prevention of moderate/severe neuro-disability or death.
FIGURE 4 | Proposed strategy for the management of PHVD.
DRIFT is however a complex intervention and involves 72 h
of intensive nursing and medical care. The process of DRIFT
was modified during the trial due to concerns over secondary
bleeds, and the trial was stopped early due to likely futility
in reaching a difference in the short-term primary outcome of
shunt or death. As an alternative approach, some units have
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reported success with more rapid clot removal (e.g., through
endoscopes) or percutaneous methods of treating intra- and
extra-axial intracranial hemorrhage, although no RCT has yet
been published with these novel treatments (39, 40). Equally,
the ELVIS trial (20) has completed its recruitment and later
neurodevelopmental outcomes are expected to be published
soon. These results are eagerly awaited as a sub-study of the
ELVIS trial has reported that, in the high-threshold group (LPs
when the VI > p97 + 4mm and anterior horn width >10mm),
there was more brain injury and higher ventricular volumes
compared to the low-threshold groups (VI > p97 and anterior
horn width>6mm) (41). There is also interest surrounding stem
cell treatment after sIVH; however, this has only been reported in
phase 1 trial (42). In lieu of the results of this research, Figure 4
shows a proposed strategy for PHVD.
PHVD is a significant cause of death and disability in
developed countries, yet few therapeutic options have so far
been trialed. Only 700 infants have been enrolled in intervention
trials, while<500 have had longer-term developmental measures
reported. While new therapies are urgently needed for these
infants, at present, NMA shows that DRIFT appears to be the
most likely candidate to improve outcomes after sIVH, but
further work is needed to implement this in routine healthcare
and promising newer therapies remain untrialed.
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